The average one-year price target for Sutro Biopharma (NasdaqGM:STRO) has been revised to $2.74 / share. This is a decrease of 13.76% from the prior estimate of $3.18 dated August 30, 2025.

The price target is an average of many targets provided by analysts. The latest targets range from a low of $0.81 to a high of $5.25 / share. The average price target represents an increase of 212.40% from the latest reported closing price of $0.88 / share.

What is the Fund Sentiment?

There are 210 funds or institutions reporting positions in Sutro Biopharma. This is an decrease of 66 owner(s) or 23.91% in the last quarter. Average portfolio weight of all funds dedicated to STRO is 0.03%, an increase of 51.67%. Total shares owned by institutions decreased in the last three months by 16.02% to 59,097K shares. The put/call ratio of STRO is 0.11, indicating a bullish outlook.

What are Other Shareholders Doing?

Suvretta Capital Management holds 6,488K shares representing 7.65% ownership of the company. In its prior filing, the firm reported owning 7,462K shares , representing a decrease of 15.01%. The firm decreased its portfolio allocation in STRO by 22.49% over the last quarter.

Kynam Capital Management holds 5,088K shares representing 6.00% ownership of the company. In its prior filing, the firm reported owning 5,441K shares , representing a decrease of 6.94%. The firm increased its portfolio allocation in STRO by 31.49% over the last quarter.

Millennium Management holds 4,732K shares representing 5.58% ownership of the company. In its prior filing, the firm reported owning 703K shares , representing an increase of 85.14%. The firm increased its portfolio allocation in STRO by 570.02% over the last quarter.

Velan Capital Investment Management holds 3,060K shares representing 3.61% ownership of the company. In its prior filing, the firm reported owning 1,030K shares , representing an increase of 66.34%. The firm increased its portfolio allocation in STRO by 213.02% over the last quarter.

Acadian Asset Management holds 3,042K shares representing 3.59% ownership of the company. In its prior filing, the firm reported owning 3,135K shares , representing a decrease of 3.04%. The firm decreased its portfolio allocation in STRO by 22.19% over the last quarter.